Tag Archives: Sanofi

How 6 Big Pharma Companies Use Twitter to Engage with Audiences

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

Pharma companies have begun to embrace different communication channels, including social media, to promote their products, present their drug development initiatives and engage with audiences worldwide.

However, make no mistake, social media is not the same for pharma companies as it is for regular users. Without proper planning, controls and staff training, firms risk fines, sanctions and worse, damage to their reputation.

Facebook, Twitter and Pinterest are the main online networks that pharmaceutical companies are eyeing. In this article, we’ll take a look at how pharma companies like Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Novartis use Twitter to maintain a close connection with their existing and potential patients.

 

Bristol-Myers Squibb

Screen Shot 2017-06-13 at 09.23.23

@bmsnews is the name of New York-based Bristol-Myers Squibb’s Twitter account. The latter was opened in April 2009 and has now has 108.000 followers. The company’s Twitter feed covers everything from drug research results and analysis, clinical collaborations with other pharma companies, to features about the company’s supply chain, and many more.

 

AstraZeneca

Screen Shot 2017-06-13 at 09.24.44

Apart from the main @AstraZeneca Twitter account, the company also has accounts for different countries (UK, US, Canada, etc) and a Twitter profile dubbed @AZhelps. The latter is destined to help people manage and support their health more confidently. The account was opened in 2009 and it currently has over 3000 followers. On the official company account, AstraZeneca posts articles and press releases related to drug discovery, tweets from different conferences, research data, etc. The account now boasts 126.000 followers.

 

GlaxoSmithKline

Screen Shot 2017-06-13 at 09.26.15

@GSK was one of the first pharma companies to be on Twitter. They created their account 10 years ago, in 2007, and now have 146.000 followers. The UK-based company also has a US version @GSKUS that it started in March 2009 and has 73.800 followers. They post R&D updates, info about conferences and events that they’re attending, studies, interviews with patients and employees, etc.

 

Pfizer

Screen Shot 2017-06-13 at 09.27.12

Apart from having separate Twitter accounts for countries like Belgium, France, Turkey, Germany, Austria, etc, @pfizer has an official Twitter profile started in 2009 which now has 206.000 followers and a channel dedicated to media announcements and investor communications dubbed @pfizer_news. Pfizer’s Twitter account is the most followed of all the big pharma Twitter accounts. It mainly focuses on the company’s initiatives in the greater therapeutic arena (like the #QuitSmoking one), cancer research, health tips, polls and surveys, etc.

 

Sanofi

Screen Shot 2017-06-13 at 09.28.33

@sanofi created its official Twitter profile in 2009 and now has 92.600 followers. The French pharma company has more than 18 Twitter accounts. It has handles for different regions – France, Canada, and the US, as well as accounts for different units like its diabetes franchise and its Genzyme unit. On the company’s official Twitter feed you can find posts related to Big Data and health initiatives, collaborations with startups to develop new health solutions, their anti counterfeiting initiatives, vaccines research and development, etc.

 

Novartis

Similar to the other pharma companies, Novartis has several Twitter handles, one for each division of the company (@NovartisPharma for the pharmaceutical division, @NovartisScience, @NovartisCancer) as well as the official page @Novartis. The latter was created in 2008 and has 216.000 followers.

Also, Novartis has one account devoted entirely to oncology clinical trials @NovartisOncCT that allows patients to find out if they qualify for trials.

On their general Twitter account, they update their audience on the latest drug research and development initiatives, post news related to partnerships and collaborations, etc.

Screen Shot 2017-06-13 at 09.29.44

In June 2014, the FDA released its social media guidance regarding the presentation of risk and benefit information which prevents pharma companies from marketing their drugs on social media without presenting the risks associated with their use. However, pharma players have found creative and useful ways of attracting and keeping their audiences engaged. Chapeau!

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.
Advertisements

Top Pharma News and Developments that Made Headlines in May

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Merck’s Keytruda got FDA approval to treat genetically ID’d tumors

merck_logo

Merck’s Keytruda was approved by the FDA to treat patients whose cancers have a specific genetic feature, making that the first time the FDA approved a cancer treatment based on a common genetic feature and not on the location where the tumor originated.

Keytruda is used for the treatment of solid tumors that have a biomarker referred to as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

 

The FDA approved first generic Strattera for the treatment of ADHD

The first generic versions of Strattera  have been approved by the FDA to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

fda

Strattera will be marketed by Apotex Inc., Teva Pharmaceuticals USA Inc., Aurobindo Pharma Limited and Glenmark Pharmaceuticals Limited.

 

Bristol-Myers Squibb entered strategic collaboration with Array BioPharma

bms

Bristol-Myers Squibb has entered a clinical research collaboration with Array BioPharma to test the latter’s investigational MEK inhibitor, binimetinib in combination with its Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen. This could be a treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.

Bristol-Myers Squibb’s Opdivo has recently been accepted for priority review in liver cancer.

 

Sanofi and Regeneron Got FDA Approval for Kevzara

Impression

Sanofi and Regeneron announced FDA approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patientswho have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).

Kevzara is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), and has been shown to inhibit IL-6R mediated signaling. IL-6 is a cytokine in the body that, in excess and over time, can contribute to the inflammation associated with RA.

In the US, Kevzara will be marketed by Regeneron and Sanofi Genzyme, the specialty care global business unit of Sanofi.

 

Novartis receives FDA approval for expanded use of Zykadia

novartis

The US Food and Drug Administration approved the expanded use of Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.

Zykadia first received accelerated approval in 2014 for patients with ALK-positive metastatic NSCLC who progressed on or are intolerant to crizotinib.

In January 2017, the FDA granted Zykadia Breakthrough Therapy designation for the first-line treatment of patients with ALK-positive metastatic NSCLC with metastases to the brain, and Priority Review for first-line ALK-positive metastatic NSCLC.

 

AstraZeneca’s Imfinzi was shown to reduce the risk of disease worsening or death in the Phase III PACIFIC trial

astrazeneca-svg

AstraZeneca and MedImmune, its global biologics research and development arm, revealed positive results for the Phase III PACIFIC trial of Imfinzi (durvalumab) as sequential treatment in patients with locally-advanced, unresectable (Stage III) non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based chemotherapy combined with radiation therapy.

AstraZeneca also received accelerated approval from the US FDA for Imfinzi in previously treated patients with advanced bladder cancer.

 

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:

  • EASL 2018 – 210 rooms in seven 4-star hotels
  • EAACI 2018 – 615 rooms in fourteen 4-star hotels
  • EHA 2018 – 1200 rooms in thirty 4-star hotels
  • ERS 2018 – 615 rooms in twenty 4-star hotels
  • EURETINA 2018 – 460 rooms in twelve 4-star hotels
  • EASD 2018 – 765 rooms in sixteen 4-star hotels
  • ECTRIMS 2018 – 620 rooms in ten hotels
  • ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.

Top Pharma News & Developments that Made Headlines in March

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

FDA approved Roche’s OCREVUS

roche

The US Food and Drug Administration (FDA) approved Roche’s OCREVUS (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis (MS).

OCREVUS reduced relapses per year by half during the two RMS Phase III studies. Furthermore, in a separate PPMS Phase III study, OCREVUS was the first and only treatment to significantly slow disability progression and reduce signs of disease activity in the brain compared with placebo with a median follow-up of three years.

The European Medicines Agency (EMA) has validated OCREVUS’ Marketing Authorisation Application (MAA) which is currently under review.

 

AstraZeneca Partnered with Circassia

astrazeneca-svg

AstraZeneca entered a strategic collaboration with respiratory biopharmaceutical company Circassia Pharmaceuticals plc. The agreement was signed for the development and commercialisation of inhaled respiratory medicines Tudorza and Duaklir in the US.

Tudorza and Duaklir are used for the treatment of chronic obstructive pulmonary disease (COPD). While Tudorza was launched in the US in 2012, Duaklir will be submitted for US regulatory review in 2018.

Under the agreement, AstraZeneca will receive a minority equity stake in Circassia while the latter will lead the promotion of Tudorza and was granted the rights to Duaklir in the US. AstraZeneca will complete ongoing development activities and continue to manufacture and supply both medicines.

 

MedImmune Formed Alliance with Sanofi Pasteur for MEDI8897

Impression

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have formed an alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897.

The two companies will jointly develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV).

MedImmune and Sanofi Pasteur will equally share all costs and profits.

 

Mylan in Global Settlement & License Agreements with Genentech and Roche on Herceptin

Mylan_Logo

In March, Mylan has agreed to the terms of a global settlement with Genentech and Roche in what concerns patents for Herceptin (trastuzumab). This enables Mylan to have global licenses for its trastuzumab product.

Under the agreement, Mylan will be able to commercialize its trastuzumab product in markets worldwide. The licenses pertain to all countries except Japan, Brazil and Mexico.

As part of the settlement, Mylan agreed to withdraw its pending Inter Partes Review (IPR) challenges against two US Genentech patents (patent numbers 6,407,213 and 6,331,415).

 

Boehringer Ingelheim Expanded Its Collaboration with Vanderbilt University

boehringer_ingelheim_logo-svg

Boehringer Ingelheim has entered a collaboration with Vanderbilt University. This adds to an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS. This molecule activates KRAS and triggers a molecular switch that plays a key role when tackling some of the deadliest types of cancer.

This collaboration has led to discoveries that might set the scene for the development of novel cancer treatment options based on molecules that are able to block this critical cancer driver.

 

Merck’s Keytruda Got FDA Nod for Treating Blood Cancer

merck_logo

Merck got a first approval from the U.S. Food and Drug Administration (FDA) under the accelerated approval program for its immunotherapy drug Keytruda as a treatment for a type of blood cancer. Keytruda is already approved for treating lung, head and neck cancers.

FDA’s accelerated approval program allows for quicker approval of drugs that fill an unmet medical need.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

January’s Top Pharma News & Developments

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

Johnson & Johnson to acquire Actelion for USD 30 billion

j-j-logo

Johnson & Johnson is set to acquire Swiss biotech company Actelion. The deal is valued at USD 30 billion and will give J&J access to Actelion’s research and development pipeline, as well as medicines for rare diseases.

Under the agreement, Actelion will draw out its research and development unit into a standalone company dubbed R&D NewCo, based in Switzerland, and led by Actelion founder and CEO Jean-Paul Clozel.

J&J will initially hold a 16% stake in R&D NewCo, with rights to an additional 16%.

 

Sanofi, MSD ended vaccines JV

Impression

Sanofi Pasteur, the vaccines division of the multinational pharmaceutical company Sanofi, has ended its vaccines joint venture with MSD, a collaboration that spanned more than 20 years.

The move was first announced in March 2016 and the reason was that both companies wanted to pursue their “distinct growth strategies.”

Throughout its existence, Sanofi Pasteur MSD launched several vaccines onto the European market such as Gardasil and Zostavax.

 

Bristol-Myers Squibb entered clinical collaboration with Janssen

bms

Global biopharmaceutical company Bristol-Myers Squibb has entered a clinical research collaboration with US-based biotechnology company Janssen Biotech.

The aim of the collaboration is to analyse the combination of Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex in Phase 1b/2 clinical studies in multiple myeloma and solid tumors.

In July 2016, Bristol-Myers Squibb and Janssen signed a clinical research collaboration to evaluate Opdivo and Live Attenuated Double-Deleted (LADD) Listerial monocytogenes cancer immunotherapy in patients with non-small cell lung cancer.

 

Merck teamed up with Palantir for faster drug discovery

merck_logo

German multinational pharma company Merck has teamed up with US-based data and analysis software company Palantir to enhance drug discovery and development.

In the beginning, the two companies will partner on three of Merck’s business sectors: healthcare, life sciences, and performance materials.

The exact terms of the deal haven’t yet been disclosed.

 

Novo Nordisk partnered Glooko to develop digital health solutions for patients with diabetes

novo_nordisk-logo

Health platform for diabetes management Glooko has teamed up with Danish multinational pharmaceutical company Novo Nordisk to develop and brand digital health solutions for people with diabetes.

Under the agreement, the companies are set to deliver personalised, digital services to support people with diabetes in what concerns treatment adherence and blood glucose management. The partnership will also make it easier for healthcare professionals to manage patients by leveraging data reporting.

Novo Nordisk’s Digital Health Platform was developed with IBM Watson Health and it aims to improve treatment outcomes.

 

Novartis in USD 1.6 bln deal with Ionis Pharmaceuticals

novartis

Novartis has entered an agreement with US-based biopharmaceutical company Ionis Pharmaceuticals.

Under the deal, Novartis will pay up to USD 1.6 billion to Ionis and its unit Akcea Therapeutics for the rights to two cardiovascular drugs that aim to lower the level of cholesterol-carrying proteins in the blood, thus reducing the risk of cardiovascular diseases. Furthermore, Novartis will invest USD 50 million in either Ionis or Akcea within the first 18 months, as well as payments worth up to USD 1.4 billion if the drugs turn out  successful.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

From 60 Pharma companies to 10 Big Pharma companies in 20 Years

We’ve all heard about Novartis, Pfizer, Sanofi and Roche. They’re some of the big guys in the pharma landscape, enjoying increased popularity, splitting the high budgets and revolutionizing the healthcare and pharma industry but what’s the road they took to get here? In order to answer that question, we’re going to analyze the 10 biggest pharma companies nowadays which used to be around 60 distinct companies 20 years ago. Here’s what they did to stand the test of time and grow.

best-pharmaceutical-companies

Novartis

It all dates back to 1970 when Ciba-Geigy was formed by the merger of J. R. Geigy Ltd and CIBA. In 1996, from the merger of Ciba-Geigy and Sandoz Laboratories, Novartis was born. In 2005, Novartis acquired Hexal and Eon Labs, thus growing its generic division Sandoz. A year later, in 2006, Novartis acquired full control of Chiron Corp. for USD 5.1 billion. In 2010, Novartis acquired the world’s largest eye-care company Alcon for USD 39.3 billion. Three years later, in 2012, the company bought Fougera Pharmaceuticals for USD 1.5 billion. In 2016, Novartis acquired Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD).

AstraZeneca (AZ)

AstraZeneca  was created in 1999 following the merger of Astra and Zeneca Group. In 2004, AZ completed its first big acquisition of Cambridge Antibody Technology. Later on, in 2007, it acquired MedImmune for about USD 15.2 billion. In 2012, AstraZeneca acquired Ardea Biosciences for USD 1.3 billion. One year later, it acquired Amylin from BMS for USD 4.3 billion and in 2015 acquired ZS Pharma for USD 2.7 billion. In 2015, AstraZeneca bought 55% majority stake in Acerta for USD 4 billion.

Pfizer

In 2000, Pfizer acquired American pharmaceutical company Warner–Lambert for USD 111.8 billion to bring its drug, Lipitor, to market. In 2002, Pfizer aimed to acquire full rights to Pharmacia’s product Celebrex and thus agreed to buy Pharmacia for stock valued at USD 60.0 billion. In 2009, Pfizer bought pharmaceutical company Wyeth for USD 68.0 billion. In 2015, Pfizer acquired Hospira for USD 15.2 billion and announced the merger with Allergan. The latter is considered to be one of the biggest mergers in pharma history. In 2016, Pfizer announced the successful completion of its acquisition of Medivation.

Sanofi

Sanofi resulted from the merger between Sanofi-Synthélabo and Aventis in 2004. The former was created in 1999 when Sanofi merged with Synthélabo. Aventis was formed in 1999 following the merger of Rhône-Poulenc S.A. with Hoechst Marion Roussel (HMR). The latter itself was formed in 1995 from the merger of Hoechst AG with Cassella, Roussel Uclaf and Marion Merrell Dow.

In 2011, Sanofi-Aventis acquired Genzyme and changed its name to Sanofi.

Johnson & Johnson

J&J was founded in 1886 as a medical devices, pharmaceutical and consumer packaged goods company. The pharmaceutical division is made up of Janssen & Cilag. In 2006, Janssen acquired the consumer healthcare business of Pfizer for USD 16.6 billion in what is considered to be the company’s largest M&A deals. In 2013, the company acquired Aragon Pharma and in 2014 it bought Alios BioPharma, Inc. for USD 1.75 billion.

Merck & Co.

Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company. Merck & Co. was established as a subsidiary of Merck in 1891, but became an independent company in 1917. It is known as MSD (Merck Sharp and Dohme) outside of North America. In 1993, Merck purchased Medco Containment Services Inc. for USD 6 billion. In 2009, Merck merged with Schering-Plough. The latter had acquired Organon from Akzo Nobel in 2007 while Organon resulted from a merger between Diosynth and Organon in 2004. Ten years later, Merck bought Cubist Pharmaceuticals for USD 8.4 billion.

Roche

Roche’s first acquisition took place in 1994 when the company bought Syntex Corporation for USD 5.3 billion. In 2002, Roche’s Japanese subsidiary Nippon Roche merged with Chugai. Following the deal, Roche got a majority stake in the Japanese company. In 2008, Roche acquired Ventana Medical Systems for USD 3.4 billion and in 2009, the company bought Genentech for USD 46.8 billion.

Teva

Teva resulted from the merger between Assia, Zori and Teva in 1976. In 2006, Teva completed its first big acquisition of IVAX Corporation for USD 7.4 billion. In 2011, it acquired Cephalon for USD 6.8 billion. After acquiring Auspex Pharma for USD 3.5 billion in 2015, Teva completed its acquisition of Allergan’s generics business (“Actavis Generics”) in 2016.

Gilead Sciences

Gilead Sciences was founded in June 1987. Over the past 16 years, the company has made several acquisitions. The biggest ones include: CV Therapeutics for USD 1.4 billion in 2009 and USD 10.4 billion acquisition of Pharmasset in 2011.

GlaxoSmithKline (GSK)

GSK was founded in 2000 following the merger of Glaxo Wellcome and SmithKline Beecham. In 2001, GSK acquired Block Drug for USD 1.2 billion. In 2009, GSK acquired Stiefel Laboratories for USD 3.6 bn. 4 years later, in 2013, GSK acquired Human Genome Sciences (HGS) for USD 3 billion. In 2015, GSK completed the acquisition of vaccine business of Novartis and sale of its oncology business to the Swiss drug major in a global deal. Under the agreement, GSK Pharma expanded its vaccine portfolio and took over 120 employees from Novartis to boost its sales in India.

There’s so much pharma history behind all of the big names out there and the evolution is far from reaching an end. We’re looking forward to seeing what these pharma giants have in store during the next couple of years and who’s going to lead the way in the M&A sector.

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are: